Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK7 | P50613 | 17/20 | 1.00 |
| ▸ | CCNH | P51946 | 16/20 | 1.00 |
| ▸ | CDK5 | Q00535 | 4/20 | 1.00 |
| ▸ | CDK1 | P06493 | 2/20 | 1.00 |
| ▸ | CDK2 | P24941 | 2/20 | 1.00 |
| ▸ | CDK9 | P50750 | 2/20 | 1.00 |
| ▸ | MNAT1 | P51948 | 2/20 | 1.00 |
| ▸ | CDK8 | P49336 | 1/20 | 1.00 |
| ▸ | CDK5R1 | Q15078 | 3/20 | 0.91 |
| ▸ | MAP3K11 | Q16584 | 2/20 | 0.91 |
| ▸ | CDK13 | Q14004 | 2/20 | 0.91 |
| ▸ | CDK12 | Q9NYV4 | 2/20 | 0.91 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.91 |
| ▸ | CCNK | O75909 | 1/20 | 0.91 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.91 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.91 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.91 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.91 |
| ▸ | EGFR | P00533 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18313553 | 1.00 | CDK7 (1.00) | CDK7CCNHCDK5CDK1CDK2 | |
| SCHEMBL30337868 | 1.00 | CDK7 (1.00) | CDK7CCNHCDK5CDK1CDK2 | |
| SCHEMBL18313531 | 0.97 | CDK7 (0.94) | CDK7CCNHCDK5CDK1CDK2 | |
| SCHEMBL14979756 | 0.96 | CDK7 (0.93) | CDK7CCNHCDK5CDK1CDK2 | |
| SCHEMBL23682983 | 0.95 | CDK7 (1.00) | CDK7CCNHCDK5CDK1CDK2 | |
| SCHEMBL14979765 | 0.95 | CDK7 (1.00) | CDK7CCNHCDK5CDK1CDK2 | |
| SCHEMBL29434968 | 0.95 | CDK7 (1.00) | CDK7CCNHCDK5CDK1CDK2 | |
| SCHEMBL18229934 | 0.95 | CDK7 (1.00) | CDK7CCNHCDK5CDK1CDK2 | |
| SCHEMBL29355500 | 0.95 | CDK7 (1.00) | CDK7CCNHCDK5CDK1CDK2 | |
| SCHEMBL18078676 | 0.95 | CDK7 (0.90) | CDK7CCNHCDK5CDK1CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 146 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4712346-A1 | COMPOSITE SUBSTRATE FOR SURFACE ACOUSTIC WAVE DEVICES | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2026-03-18 | — | — | EP | claimed |
| EP-4695235-A1 | NOVEL GSPT1 DEGRADER AND USE THEREOF | Cyrus Therapeutics Inc. (KR) | 2026-02-18 | — | — | EP | claimed |
| EP-4529926-A1 | METHOD FOR TREATING CANCER BY COMBINING ALKYLATING AGENT PRODRUG AND CELL CYCLE INHIBITOR | Ascentawits Pharmaceuticals, Ltd. (CN) | 2025-04-02 | — | — | EP | claimed |
| CN-119233822-A | Methods of treating cancer using alkylating agent prodrugs and cell cycle inhibitors in combination | 深圳艾欣达伟医药科技有限公司 | 2024-12-31 | — | — | CN | claimed |
| WO-2024232192-A1 | COMPOSITE SUBSTRATE FOR SURFACE ACOUSTIC WAVE DEVICES | 信越化学工業株式会社 | 2024-11-14 | — | — | WO | claimed |
| CN-118938466-A | Super-surface cascading system for terahertz phase contrast imaging and design method thereof | 北京理工大学 | 2024-11-12 | — | — | CN | claimed |
| US-12135282-B2 | Method of imaging a sample material | THE UNIVERSITY OF WESTERN AUSTRALIA (AU) | 2024-11-05 | — | — | US | claimed |
| WO-2024215130-A1 | NOVEL GSPT1 DEGRADER AND USE THEREOF | CYRUS THERAPEUTICS INC. (KR) | 2024-10-17 | — | — | WO | claimed |
| CN-115078300-B | High-resolution terahertz characteristic spectral line precision test device and test method | 中电科思仪科技股份有限公司 | 2024-07-26 | — | — | CN | claimed |
| CN-117291094-B | Unmanned aerial vehicle power system parameter anomaly detection method based on associated parameter mapping | 成都飞机工业（集团）有限责任公司 | 2024-07-12 | — | — | CN | claimed |
| WO-2024073399-A2 | DNA-AFFIBODY-DRUG NANOSTRUCTURES FOR INHIBITING TRIPLE NEGATIVE BREAST CANCER GROWTH AND METASTASIS | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2024-04-04 | — | — | WO | claimed |
| WO-2023226959-A1 | METHOD FOR TREATING CANCER BY COMBINING ALKYLATING AGENT PRODRUG AND CELL CYCLE INHIBITOR | 深圳艾欣达伟医药科技有限公司 | 2023-11-30 | — | — | WO | claimed |
| CN-116612639-A | Terahertz-based pedestrian crossing application recognition control method | 维特瑞交通科技有限公司 | 2023-08-18 | — | — | CN | claimed |
| US-20230210852-A1 | METHODS OF TREATING CANCER IN PATIENTS WITH AN ANOMALOUS KRAS GENE OR DELETIONS WITHIN CHROMOSOME 9 | MEDIC LIFE SCIENCES, INC. | 2023-07-06 | — | — | US | claimed |
| EP-4157465-A2 | METHODS OF TREATING CANCER IN PATIENTS WITH AN ANOMALOUS KRAS GENE OR DELETIONS WITHIN CHROMOSOME 9 | Syros Pharmaceuticals, Inc. (US) | 2023-04-05 | — | — | EP | claimed |
| CN-112670792-B | Device for simultaneously generating multi-frequency terahertz waves based on optimized cascade difference frequency | 华北水利水电大学 | 2023-03-24 | — | — | CN | claimed |
| US-20220305003-A1 | METHODS OF TREATING CANCER WITH AN INHIBITOR OF ZNF827 | CHILDREN'S MEDICAL RESEARCH INSTITUTE (AU) | 2022-09-29 | — | — | US | claimed |
| CN-115078300-A | High-resolution terahertz characteristic spectral line precision testing device and testing method | 中电科思仪科技股份有限公司 | 2022-09-20 | — | — | CN | claimed |
| US-20220276161-A1 | A METHOD OF IMAGING A SAMPLE MATERIAL | THE UNIVERSITY OF WESTERN AUSTRALIA (AU) | 2022-09-01 | — | — | US | claimed |
| EP-3982977-A1 | METHODS OF TREATING CANCER WITH AN INHIBITOR OF ZNF827 | Children's Medical Research Institute (AU) | 2022-04-20 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230210852-A1 | METHODS OF TREATING CANCER IN PATIENTS WITH AN ANOMALOUS KRAS GENE OR DELETIONS WITHIN CHROMOSOME 9 | CDKL5, KRAS, CDK9 | CDK7 12/4885CCNH 255/4885CDK5 71/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.